

The Angel Fund for ALS Research Hosted International *Angels Over Boston* Conference to Advance the Fight Against ALS

(Boston, MA) – The Angel Fund for ALS Research recently brought together leading researchers and clinicians from around the world for its first international conference dedicated to advancing research that will lead to effective treatments—and ultimately a cure—for Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s Disease. The conference, *Angels Over Boston*, focused on emerging therapeutic approaches leading to treatment.

The two-day scientific workshop was attended by internationally recognized ALS researchers and clinicians from the United States, Israel, France, Sweden, Greece and Germany.

According to an Angel Fund spokesperson, this important scientific gathering was designed to foster collaboration and exchange information for groundbreaking research aimed at advancing promising therapies from the laboratory to patients.

Conferences like *Angels Over Boston* are essential because they accelerate the exchange of scientific ideas that may lead to earlier diagnosis, slower disease progression, and more effective therapies. By bringing together leading academic researchers and clinician-scientists from across the globe, The Angel Fund can help move promising discoveries closer to patients who need them the most and to shorten the path from scientific discovery to patient impact.

The conference provided a unique opportunity for these researchers and clinicians who have dedicated their careers to not only understanding ALS, but also to move us closer to effective treatment, and ultimately, a cure.

As a leading voice of The Angel Fund for ALS Research and its commitment to funding promising ALS research, President Rich Kennedy is living with his own ALS diagnosis and has lost his father and two brothers to the disease.

“The Angel Fund was founded by families who have experienced ALS firsthand,” Kennedy said. “It’s why we’ve raised and invested millions of dollars in cutting-edge ALS research, and why more than 92% of our expenditures are directed to this research. It’s also why

we support groundbreaking work by world-renowned scientists and other dedicated researchers like those at the conference who are pursuing gene therapies, biomarkers, and the next generation of ALS treatments. And it's why The Angel Fund for ALS Research has expanded this commitment to push toward treatment focused on veterans living with ALS."

At the conclusion of the conference, the researchers had an opportunity to meet with ALS families to hear their stories and to answer their questions about the advancement of ALS therapies and treatments.

The Angel Fund is grateful to both the families who shared their own stories and reminded everyone that behind every research breakthrough is an individual and family waiting for hope and to the researchers and clinicians who joined us for this extraordinary opportunity.

-30-

About The Angel Fund for ALS Research

The Angel Fund for ALS Research (Angel Fund, Inc – 04-3478977) located in Wakefield, MA is an independent 501(c)(3) nonprofit organization dedicated to supporting research into amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

The Angel Fund's mission is to raise funds through events, campaigns, foundation grants, and community outreach to support ALS research aimed at finding the cause, treatment, and cure for the disease. The organization operates with minimal overhead—no rent, utility bills, or high-paid executives—allowing over 92% of its expenditures to directly fund research.

The Angel Fund for ALS Research is dedicated to accelerating the discovery of effective treatments and a cure for ALS through innovative, patient-focused research. For more than 25 years, the organization has supported groundbreaking scientific initiatives and collaborations that bring hope to individuals and families impacted by ALS.

